Group 1 - The core point of the article is that Baike Biological has received the Drug Registration Certificate for its nasal spray influenza attenuated live vaccine from the National Medical Products Administration [1] Group 2 - The announcement was made on the evening of August 25, indicating a significant regulatory milestone for the company [1] - The approval of the vaccine may enhance the company's product portfolio and market position in the biopharmaceutical industry [1] - This development reflects the ongoing efforts in the industry to innovate and provide effective vaccination options against influenza [1]

Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Baike Biological, received the drug registration certificate for a nasal spray influenza live attenuated vaccine from the National Medical Products Administration [1] Group 1: Product Details - The vaccine is a nasal formulation with a specification of 0.2ml per dose [1] - It is intended for use in individuals aged 3 to 17 years [1] Group 2: Business Impact - The approval is expected to facilitate the promotion and use of Baike Biological's influenza vaccine, optimizing the company's product structure [1] - This development is anticipated to further enhance the company's core competitiveness [1] Group 3: Market Considerations - There is uncertainty regarding the timeline for the vaccine's market launch and sales [1]

证券代码：688276 证券简称：百克生物 公告编号：2025-028 长春百克生物科技股份公司 受理号：CXSS2400043 关于自愿披露鼻喷流感减毒活疫苗上市许可申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、长春百克生物科技股份公司（以下简称"公司"）近日收到国家药品监督 管理局下发的鼻喷流感减毒活疫苗《药品注册证书》。 2、本次鼻喷流感减毒活疫苗取得药品注册证书后尚需取得产品批签发证明并 完成各地准入等程序，上市销售时间具有一定的不确定性。敬请广大投资者谨慎决 策，注意防范投资风险。 现将相关情况公告如下： 一、《药品注册证书》的主要信息 证书编号：2025S02547 药品名称：鼻喷流感减毒活疫苗 剂型：鼻用制剂 规格：每支 0.2ml。每 1 次人用剂量为 0.2ml，含 A（H1N1）型和 A（H3N2） 型流感减毒活病毒滴度均应不低于 6.9 lg EID50，B 型流感减毒活病毒滴度应不低于 6.4 lg EID50。 注册分类：预防用生物制品 药品批准文号：国药 ...

Group 1 - The core point of the article is that Baike Biotech (688276.SH) has received the Drug Registration Certificate for a nasal spray live attenuated influenza vaccine from the National Medical Products Administration [1] - The newly approved vaccine simulates natural infection by the influenza virus through nasal administration, creating an immune barrier in the respiratory tract against influenza virus invasion [1] - This vaccine is an upgraded liquid formulation from the previously marketed lyophilized nasal spray live attenuated influenza vaccine, eliminating the need for reconstitution during use, making it more convenient for administration [1] - The target population for this vaccine is individuals aged 3 to 17 years [1]

Core Viewpoint - The company, Baike Biotech (688276.SH), has received the Drug Registration Certificate for a nasal spray live attenuated influenza vaccine from the National Medical Products Administration, marking a significant advancement in its product offerings [1] Group 1: Product Development - The newly approved nasal spray influenza vaccine simulates natural infection by the influenza virus, establishing an immune barrier in the respiratory tract to prevent viral invasion [1] - This vaccine is an upgraded liquid formulation from the previously available freeze-dried version, eliminating the need for reconstitution during use, thus enhancing convenience for administration [1] - The target population for this vaccine includes individuals aged 3 to 17 years [1]

Group 1 - The core point of the article is that Baike Biological has received approval for its nasal spray influenza live attenuated vaccine from the National Medical Products Administration [1] - The vaccine is classified as a preventive biological product and is intended for the age group of 3 to 17 years [1] - The vaccine is in a nasal formulation with a specification of 0.2ml per dose [1]

Core Viewpoint - The company has received the drug registration certificate for the nasal spray influenza live attenuated vaccine from the National Medical Products Administration, which is expected to enhance the promotion and use of its influenza vaccine products [1] Group 1: Product Development - The vaccine is suitable for individuals aged 3 to 17 years and is administered via the nasal route, creating an initial immune barrier against influenza virus invasion in the respiratory tract [1] - The vaccine formulation has been upgraded from a freeze-dried form to a liquid form, making it more convenient for use [1] Group 2: Market Impact - The approval of this vaccine is anticipated to optimize the company's product structure and strengthen its core competitiveness in the market [1] - There is uncertainty regarding the timeline for the vaccine's market launch and sales, which presents potential investment risks [1]

证券代码：688276 证券简称：百克生物 公告编号：2025-027 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 9 月 1 日（星期一）上午 09:00-10:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 8 月 25 日（星期一）至 8 月 29 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@bchtpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回 答。 长春百克生物科技股份公司（以下简称"公司"）将于 2025 年 8 月 30 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 9 月 1 日（星期一）上午 09:00-10:0 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688276 | 百克生物 | 25.40 | 8.09% | 11.19万 | 2.75亿 | | 688520 | 神州细胞 | 73.20 | 6.94% | 15.40万 | 11.00亿 | | 688331 | 荣昌生物 | 76.99 | 4.35% | - 14.02万 | 10.53亿 | | 300239 | 东宝生物 | 5.94 | 3.85% | 19.94万 | 1.17亿 | | 688163 | 赛伦生物 | 26.15 | 3.81% | 2.75万 | 7126.14万 | | 300841 | 康华生物 | 92.06 | 3.67% | 6.31万 | 5.74亿 | | 301166 | 优宁维 | 33.75 | 2.99% | 1.91万 | 6363.30万 | | 688177 | 百圆泰 | 33.29 | 2.91% | 4.75万 | 1.56亿 | | 600739 | 辽宁成大 | + 1 ...

Market Overview - The Shanghai Composite Index closed at 3696.77 points, above the annual line, with an increase of 0.83% [1] - The total trading volume of A-shares reached 22,728.38 billion yuan [1] Stocks Breaking Annual Line - A total of 97 A-shares have surpassed the annual line today, with notable stocks showing significant deviation rates [1] - The stocks with the highest deviation rates include: - Mingyang Electric: 8.12% deviation, closing price at 43.45 yuan, with a daily increase of 14.49% and turnover rate of 11.79% [1] - Baike Biological: 6.78% deviation, closing price at 25.40 yuan, with a daily increase of 8.09% and turnover rate of 2.70% [1] - ST Lianchuang: 5.16% deviation, closing price at 5.49 yuan, with a daily increase of 5.78% and turnover rate of 3.46% [1] Additional Stocks with Minor Deviations - Other stocks that have just crossed the annual line with smaller deviation rates include: - Times Electric: 3.99% deviation, closing price at 4.01 yuan, with a daily increase of 4.16% and turnover rate of 1.11% [1] - Xinda Real Estate: 3.99% deviation, closing price at 39.82 yuan, with a daily increase of 8.35% and turnover rate of 5.62% [1] - China National Materials: 3.76% deviation, closing price at 9.01 yuan, with a daily increase of 4.16% and turnover rate of 3.74% [1]